Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24, 86
eCollection

Predictors of 5 Year Survival Rate in Hepatocellular Carcinoma Patients

Affiliations

Predictors of 5 Year Survival Rate in Hepatocellular Carcinoma Patients

Arash Sarveazad et al. J Res Med Sci.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignancies and growing challenges of global health. In this study, for the first time in Iran, we investigated the 5-year survival rate and prognostic factors in patients with HCC.

Materials and methods: In this historical cohort study, we examined the medical records of 227 HCC patients who were registered in the central tumor registry of our institution from September 2007 to September 2017. Demographic data, clinical parameters, received treatments, and survival curves from time of diagnosis were evaluated. Kaplan-Meier was used for univariate analysis, and multivariable analysis was performed by Cox regression.

Results: A total of 208 (91.63%) patients were dead. The 5-year survival rate was estimated 19 (8.37%). The average follow-up in this study was 14.3 months. Overall median survival rate was 12.1 months. Univariate analysis showed that tumor size, metastasis, number of involved lymph node, hepatitis type, and treatment were significantly related to the survival rate, and Cox regression analysis revealed that the tumor size >3 cm (hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.68-4.97; P = 0.027), involved lymph nodes >2 (HR = 4.12, 95% CI = 2.66-6.38; P = 0.001), metastasis (HR = 3.87, 95% CI = 3.13-6.54; P = 0.011), combination therapy with surgery and chemotherapy (HR = 0.4, 95% CI = 0.15-0.79; P = 0.023), and coinfection with hepatitis B virus and hepatitis C virus (HR = 2.11, 95% CI = 1.81-4.6; P = 0.036) are the most relevant prognostic factors with 5-year survival rate in patients with HCC.

Conclusion: Results of this study will help estimate survival rates for patients with HCC according to their clinical status.

Keywords: Five-year survival rate; hepatocellular carcinomas; prognostic factors.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier chart, 5-year survival rate of 227 hepatocellular carcinoma patients
Figure 2
Figure 2
Five-year survival rate (Kaplan–Meyer) of patients with hepatocellular carcinoma based on the clinical and pathologic characteristics of patients

Similar articles

See all similar articles

References

    1. Tunissiolli NM, Castanhole-Nunes MM, Pavarino ÉC, da Silva RF, da Silva RC, Maria Goloni-Bertollo E. Clinical, epidemiological and histopathological aspects in patients with hepatocellular carcinoma undergoing liver transplantation. Asian Pac J Cancer Prev. 2018;19:2795–802. - PMC - PubMed
    1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol. 2013;58:593–608. - PubMed
    1. Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2009;286:5–8. - PubMed
    1. Kirchner G, Kirovski G, Hebestreit A, Schölmerich J, Schlitt HJ, Stoeltzing O, et al. Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med. 2010;3:169–79. - PMC - PubMed
    1. Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: An analysis of 1066 cases of a German HCC registry. J Clin Gastroenterol. 2014;48:279–89. - PubMed
Feedback